Arming androgen receptors to oppose oncogenic estrogen receptor activity in breast cancer

Simple item page
dc.contributor.authorHickey, T.E.
dc.contributor.authorDwyer, A.R.
dc.contributor.authorTilley, W.D.
dc.date.issued2021
dc.descriptionPublished online: 22 July 2021
dc.description.abstractMost breast cancers are driven by oncogenic activity of the estrogen receptor alpha (ER). Resistance to ER target therapies is the major cause of breast cancer death. Recently, there has been renewed interest in targeting the androgen receptor (AR) to treat ER-driven breast cancers. Herein, we discuss evidence for an AR agonist, not antagonist, treatment strategy.
dc.description.statementofresponsibilityTheresa E. Hickey, Amy R. Dwyer and Wayne D. Tilley
dc.identifier.citationBritish Journal of Cancer, 2021; 125(12):1599-1601
dc.identifier.doi10.1038/s41416-021-01478-8
dc.identifier.issn0007-0920
dc.identifier.issn1532-1827
dc.identifier.orcidHickey, T.E. [0000-0002-2752-730X]
dc.identifier.orcidDwyer, A.R. [0000-0002-4422-1433]
dc.identifier.orcidTilley, W.D. [0000-0003-1893-2626]
dc.identifier.urihttp://hdl.handle.net/2440/131691
dc.language.isoen
dc.publisherSpringer Nature
dc.relation.granthttp://purl.org/au-research/grants/nhmrc/1084416
dc.relation.granthttp://purl.org/au-research/grants/nhmrc/1130077
dc.rights© The Author(s), under exclusive licence to Springer Nature Limited 2021. Published on Behalf of CRUK
dc.source.urihttps://doi.org/10.1038/s41416-021-01478-8
dc.subjectHumans
dc.subjectBreast Neoplasms
dc.subjectReceptors, Androgen
dc.subjectReceptors, Estrogen
dc.subjectFemale
dc.titleArming androgen receptors to oppose oncogenic estrogen receptor activity in breast cancer
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Medicine publications